Biomea Fusion Q1 net loss narrows as expenses fall

Biomea Fusion

11/05/2026 22:05

Overview

US diabetes and obesity drug developer's Q1 net loss narrowed yr/yr

Operating expenses for Q1 fell sharply, driven by lower clinical activity and a decrease in headcount

Company projects cash runway into Q1 2027, supporting ongoing clinical trials

Outlook

Biomea Fusion projects cash runway into Q1 2027

Result Drivers

LOWER CLINICAL ACTIVITY - Decreased clinical activities led to lower R&D expenses in Q1

HEADCOUNT REDUCTION - Lower personnel-related expenses, including stock-based compensation, due to reduced headcount

COST CONTROL - Decreases in consultant, advisor, rent, and facilities-related costs contributed to lower operating expenses

Company press release: ID:nGNX83ZSQx

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$12.40 mln
Q1 Basic EPS
-$0.17


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Biomea Fusion Inc is $7.00, about 354.5% above its May 8 closing price of $1.54

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)